Rocuronium-induced neuromuscular block and reversibility with sugammadex at the corrugator supercilii and adductor pollicis muscles

Rocuronium-induced neuromuscular block and reversibility with sugammadex at the corrugator supercilii and adductor pollicis muscles - Rocuronium and sugammadex at the corrugator supercilli

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010240

Enrollment

Registered

2013-03-14

Start date

2013-03-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Surgical patients requiring general anesthesia

Interventions

The patients will recive sugammadex 2mg/kg when the height of the twich in a train of four(TOF) stimlation willbe maintained at 10% of the control, and the time requred for the facilitated recovery to

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients aged 20 years old and above 2) ASA risk classification 1 and 2 3) Patients consented to participate in this study

Exclusion criteria

Exclusion criteria: 1)Patients having allergic factors to neuromuscular blocking agents 2) ASA risk 4 and above 3) BMI 30 and above or below 18.5 4)Patients having hepatic and renal disorders

Design outcomes

Primary

Measure	Time frame
Optimum dose of sugammadex for the reversal of neuromuscular blockade at the corrugator supercilii muscle.	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026